Dyslipidemia (particularly atherogenic dyslipidemia) does not respond well to statins, which partly explains the residual cardiovascular risk observed in patients on statins.8,9 Several studies report that inhibitors of the plasma protein PCSK9 substantially reduce the residual cardiovascular risk when combined with statins.8,10–12 However, almost all of the studies on the relationship between PCSK9 and cardiovascular disease are conducted in developed countries. The gene discussed is PCSK9; the disease is metabolic syndrome.